標(biāo)題：Research Grade Monalizumab 莫那利珠單抗,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/266.html

名稱：Research Grade Monalizumab莫那利珠單抗

別名：Monalizumab莫那利珠單抗，IPH-2201, NN-8765, NNC-0141-0000-0100, NNC-141-01000, monolizumab,anti-NKG2A, humZ270

CAS: 1228763-95-8

貨號(hào)：DHD71901

適用物種：Human

寄主物種：Humanized

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：IgG4-kappa

應(yīng)用：Research Grade Biosimilar

UniProt：P26715

靶點(diǎn)：KLRC1, NKG2-A/NKG2-B type II integral membrane protein, NKG2-A/B-activating NK receptor, CD159 antigen-like family member A, CD159a, NK cell receptor A, NKG2A

用途范圍：僅用于科研

儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購(gòu)買聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

 

參考文獻(xiàn)：

Monalizumab: inhibiting the novel immune checkpoint NKG2A. PMID: 31623687

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. PMID: 35452273

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. PMID: 30503213

Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors. PMID: 36852723

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. PMID: 38309722

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial. PMID: 37393645

Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. PMID: 36547689

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. PMID: 37707791

Immunotherapy in Head and Neck Cancer: Where Do We Stand? PMID: 37213060

Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer. PMID: 33501768

Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. PMID: 37782273

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. PMID: 34638090

NKG2A blocks the anti-metastatic functions of natural killer cells. PMID: 36787695

Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. PMID: 31308062

[New frontiers in the fight against cancer]. PMID: 30973133

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. PMID: 35254876

NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy. PMID: 36831606

Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. PMID: 32344314

NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E. PMID: 35596615

The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. PMID: 32409305

Inhibitory NKG2A+ and absent activating NKG2C+ NK cell responses are associated with the development of EBV+ lymphomas. PMID: 37426645

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. PMID: 27853650

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. PMID: 32967162

Killer to cure: Expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors. PMID: 36811226

NK cell-based therapies for HIV infection: Investigating current advances and future possibilities. PMID: 34668588

Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer. PMID: 38468260

Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy. PMID: 30645023

A novel Natural killer cell-related gene signature for improving the prediction of prognosis and immunotherapy response in bladder cancer. PMID: 37653625

Born to Kill: NK Cells Go to War against Cancer. PMID: 30898260

High-Density of FcγRIIIA+ (CD16+) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis. PMID: 34211852